CG Oncology (CGON) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$0.57
- EPS estimate
- −$0.56
- EPS surprise
- −1.97%
- Revenue surprise
- +2706.41%
- Revenue
- $1.7M
- Revenue estimate
- $59,364.00
- Reported
- Nov 14, 2025
CG Oncology's most recent report in the table covers Q3 2025 and was released on November 14, 2025. It posted a loss of $0.57 per share, slightly wider than the $0.56 loss expected, a 1.97% miss. Revenue was $1.7 million against an estimate of about $59,000. The table has no Q3 2024 row, so there is no year-earlier comparison for this quarter.
The record is short and incomplete. It holds five quarters: Q2 2024, Q4 2024 and the first three quarters of 2025. Every quarter shown was a loss, and the loss per share widened through 2025, from $0.45 in Q1 to $0.54 in Q2 and $0.57 in Q3. Revenue has been very small, ranging from $52,000 to $1.7 million where reported, and Q2 2025 revenue is not given. CG Oncology beat the EPS estimate only once, in Q2 2024. The other four quarters came in with wider losses than expected.
The table contains no results after Q3 2025, so Q4 2025 and the 2026 quarters are not shown here. Past reports came in late March, mid-May, early August and mid-November. Newer results, once added, will show whether the per-share losses kept widening.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 14, 2025 | −$0.56 | −$0.57 | −1.97% | $1.7M | SEC |
| Q2 2025 | Aug 8, 2025 | −$0.47 | −$0.54 | −15.98% | $0.00 | SEC |
| Q1 2025 | May 13, 2025 | −$0.40 | −$0.45 | −11.50% | $52,000.00 | SEC |
| Q4 2024 | Mar 28, 2025 | −$0.35 | −$0.46 | −33.22% | $459,000.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.36 | −$0.28 | +21.35% | $111,000.00 | SEC |
Quarterly revenue
Frequently asked questions
When did CG Oncology (CGON) last report earnings?
CG Oncology last reported on Nov 14, 2025, covering fiscal Q3 2025.
Did CGON beat earnings estimates?
No. CG Oncology reported EPS of −$0.57 for Q3 2025 against a −$0.56 estimate — a 1.97% miss.
How much revenue did CGON report last quarter?
CG Oncology reported $1.7M in revenue for Q3 2025, against a consensus estimate of $59,364.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.